search

Lipocine Inc (LPCN)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Nov 11, 2026

Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine Inc. has announced that the first participant has been dosed in its BLOOM Phase 3 study for LPCN 1154, an oral brexanolone formulation for postpartum depression (PPD). This 48-hour oral treatment is designed for at-home use, with topline results from the 120-participant study expected in the second half of 2027. The study incorporates insights from a previous Phase 3 trial and FDA feedback to enhance site and data quality.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
Lipocine Announces Financial Results for the Third Quarter of 2026
Nov 5, 2026

Lipocine Announces Financial Results for the Third Quarter of 2026

Lipocine Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $0.7 million and total revenue of $2.3 million. The company also provided a corporate update on its drug candidates, including the initiation of the BLOOM study for LPCN 1154 for Postpartum Depression and regulatory approvals for TLANDO® in Canada and the UAE. As of November 4, 2026, Lipocine had approximately $28.5 million in unrestricted cash, cash equivalents, and marketable investment securities.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish